Journal
NATURE REVIEWS CANCER
Volume 11, Issue 8, Pages 558-572Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3090
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia
- Cancer Institute New South Wales
- National Breast Cancer Foundation
- Cure Cancer Australia Foundation
- Australian Cancer Research Foundation
- Petre Foundation
- Young Garvan and the RT Hall Trust
Ask authors/readers for more resources
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
